PDCD1 and cancer: During ICI treatment, pre‐existing mutations may disappear, while more complex de novo mutations arise, along with a shift in the T cell repertoire, therefore, cancer cells could bypass immune detection independently of the PD‐1 pathway, contributing to ICI resistance [79].